Interview with Mats Nilsson, serial entrepreneur at SciLifeLab
Sciety had the opportunity to ask a few questions to Mats Nilsson, professor at SciLifeLab and co-founder of EMPE Diagnostics and several other biotechnology companies. In the interview he talks about EMPE Diagnostics’ planned establishment in India and and about the need for diagnostic tools in order to use the drugs that are available. He gives an insight into SciLifeLab as the platform for developing ideas and also his view on the role of research in society.
Read moreThe Sciety syndicate invests in Synartro that develops a novel drug for osteoarthritis
The Sciety syndicate invests in Synartro, which uses existing drugs with proven efficacy to develop an improved drug treatment of…
Read more
The investment syndicate
Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.
Read more about the Sciety investment syndicate and membership
Services we offer
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What our clients say
“Athera chose to work with Sciety as they have an effective process for capital acquisition combined with specialist competence in life science and a strong network of investors. With the help of Sciety, Athera could execute their share issue in a short amount of time. Both management and owners are very satisfied with the cooperation with Sciety."
Carina Schmidt, CEO of Athera Biotechnologies
Read more about Sciety and find out what our clients say about working with us
Investment areas
Biotechnology
From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.
Medical technology
From clinical validation phase to expansion phase.
Pharmacology
From late preclinical phase to Phase II clinical trials. All therapeutic areas.
Diagnostics
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value-enhancing healthcare.
Health tech
From early sales to expansion phase. Preventive health and medical services.
Current investment opportunities
Receive information about upcoming investment opportunities
Sign up to receive information about upcoming investment opportunities and invitations to investor lunches with the companies' executive management teams.
Selection of executed investments
Synartro
Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.
Cavis Technologies
Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.
Elypta
Elypta has developed a new method for early cancer diagnosis. Liquid Biopsy is a rapidly growing field that is expected to be of great importance for cancer diagnosis.
Athera Biotechnologies
The company is in Phase II with a pharmaceutical candidate for a life-threatening illness for which there are currently no sufficient therapies.